Clinical Trial Detail

NCT ID NCT03876769
Title Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients (CASSIOPEIA)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

B-cell adult acute lymphocytic leukemia

childhood B-cell acute lymphoblastic leukemia

Therapies

Tisagenlecleucel

Age Groups: adult child

No variant requirements are available.